<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
OCTOBER 3, 2000
(Date of Report)
NEORX CORPORATION
------------------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
<TABLE>
<S> <C> <C>
WASHINGTON 0-16614 91-1261311
(State or Other Jurisdiction (Commission File No.) (IRS Employer
of Incorporation) Identification No.)
</TABLE>
410 WEST HARRISON STREET, SEATTLE, WASHINGTON 98119-4007
(Address of principal executive offices) (Zip Code)
(206) 281-7001
(Registrant's telephone number, including area code)
<PAGE> 2
ITEM 5. OTHER EVENTS
The Company has initiated Phase III clinical trials of its Skeletal
Targeted Radiotherapy (STR) for the treatment of multiple myeloma.
See Exhibit 99.1 for additional information.
ITEM 7. EXHIBITS
99.1 Press release dated October 2, 2000
-2-
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NEORX CORPORATION
Dated: October 3, 2000 By /s/ RICHARD L. ANDERSON
-------------------------------------
Richard L. Anderson
President and Chief Operating Officer
-3-
<PAGE> 4
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit No.
-----------
<S> <C>
99.1 Press Release dated October 2, 2000
</TABLE>
-4-
